Physician profile
Dawn Little
NPI 1578221636
$2,497.78
in general payments reported to CMS, 2019-2025
45 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $394 · 2023: $312 · 2024: $424 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $350.75 | 2022-2025 | |
| Novo Nordisk INC | $240.07 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $205.12 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $198.22 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $151.71 | 2023-2025 | Enhertu, Calquence, Airsupra |
| Amgen INC. | $142.35 | 2022-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $113.59 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $63.11 | 2024-2025 | Rexulti |
| Daiichi Sankyo INC. | $55.27 | 2025 | Datroway |
| Array Biopharma INC | $53.96 | 2025 | Braftovi, Mektovi, Lorbrena |
| Celgene Corporation | $48.02 | 2025 | Reblozyl |
| Exact Sciences Corporation | $47.49 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $43.14 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Sanofi Pasteur INC. | $34.22 | 2023 | |
| Stemline Therapeutics INC. | $33.89 | 2025 | Orserdu |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.